A majority of House Republican lawmakers recently released a budget plan that proposed once again banning Medicare from negotiating prescription drug prices — a move it justified with theatrical language and highly misleading data.
The Republican Study Committee (RSC), which represents roughly 80 percent of House Republican lawmakers, accused President Joe Biden and congressional Democrats of embracing “socialist price controls that will limit access to life-saving drugs for those who desperately need them,” by enacting a pilot program allowing Medicare to negotiate prices on a handful of medicines for the first time.
According to a recent RAND Corporation study, drug companies charge 278 percent higher prices for medicines in the United States than in other wealthy countries.
The issue brief from the University of Chicago notes that its “innovation estimates are 27 times larger than CBO’s,” based on its authors’ “preferred methodology.”
The University of Chicago study and issue brief were both led by Tomas Philipson, a former Trump administration economic official with deep ties to the pharmaceutical industry.
According to ProPublica, Philipson previously led a consulting firm that worked for two dozen drug companies and industry groups, including the powerful lobby Pharmaceutical Research and Manufacturers of America (PhRMA).
The original article contains 642 words, the summary contains 199 words. Saved 69%. I’m a bot and I’m open source!
This is the best summary I could come up with:
A majority of House Republican lawmakers recently released a budget plan that proposed once again banning Medicare from negotiating prescription drug prices — a move it justified with theatrical language and highly misleading data.
The Republican Study Committee (RSC), which represents roughly 80 percent of House Republican lawmakers, accused President Joe Biden and congressional Democrats of embracing “socialist price controls that will limit access to life-saving drugs for those who desperately need them,” by enacting a pilot program allowing Medicare to negotiate prices on a handful of medicines for the first time.
According to a recent RAND Corporation study, drug companies charge 278 percent higher prices for medicines in the United States than in other wealthy countries.
The issue brief from the University of Chicago notes that its “innovation estimates are 27 times larger than CBO’s,” based on its authors’ “preferred methodology.”
The University of Chicago study and issue brief were both led by Tomas Philipson, a former Trump administration economic official with deep ties to the pharmaceutical industry.
According to ProPublica, Philipson previously led a consulting firm that worked for two dozen drug companies and industry groups, including the powerful lobby Pharmaceutical Research and Manufacturers of America (PhRMA).
The original article contains 642 words, the summary contains 199 words. Saved 69%. I’m a bot and I’m open source!